SOUTHLAKE, Texas, March26, 2026 /PRNewswire/ — Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusingon the prevention and treatment of cardio, renal and metabolic diseases, today announcedits participation in the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.
Company management will meet with investors in one-on-one meetings during the conference.
About RenibusTherapeutics
Renibus Therapeutics® is a clinical late-stage biopharmaceutical company focused on the prevention and treatment of cardiac, renal, and metabolic diseases. Renibus’ lead program, veverimer, is currently in Phase 3 development for the treatment of metabolic acidosis in adults with chronic kidney disease. The Company’s second late-stage program, RBT-1, recently completed the PROTECT Phase 3 trial evaluating RBT-1 in patients undergoing cardiac surgery. Results from this trial suggest that further development in risk-enriched patients may be warranted and is currently under evaluation.
For more information, please visit the Company’s website at www.Renibus.com and engage with us on LinkedIn.
Investor and Media Contact
Amy Conrad
Juniper Point
[emailprotected]
858-914-1962
Business Development Contact
Jamie Donadio
CFO, Renibus
[emailprotected]
SOURCE Renibus Therapeutics